Compare TLX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLX | CNS |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | Australia | United States |
| Employees | 1184 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | N/A | 2004 |
| Metric | TLX | CNS |
|---|---|---|
| Price | $10.23 | $81.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $21.13 | ★ $71.50 |
| AVG Volume (30 Days) | 146.1K | ★ 305.8K |
| Earning Date | 08-19-2026 | 04-16-2026 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $427,536,000.00 |
| Revenue This Year | N/A | $4.71 |
| Revenue Next Year | N/A | $4.37 |
| P/E Ratio | $150.33 | ★ $97.54 |
| Revenue Growth | N/A | ★ 4.07 |
| 52 Week Low | $6.28 | $58.39 |
| 52 Week High | $14.27 | $84.93 |
| Indicator | TLX | CNS |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 59.11 |
| Support Level | $10.12 | $60.24 |
| Resistance Level | $11.38 | $84.93 |
| Average True Range (ATR) | 0.26 | 2.99 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 3.74 | 70.34 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $99.5 billion in managed assets at the end of May 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.